Olanzapine Mylan

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

olanzapine

Disponibbli minn:

Mylan Pharmaceuticals Limited

Kodiċi ATC:

N05AH03

INN (Isem Internazzjonali):

olanzapine

Grupp terapewtiku:

Psycholeptics

Żona terapewtika:

Schizophrenia; Bipolar Disorder

Indikazzjonijiet terapewtiċi:

AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Sommarju tal-prodott:

Revision: 19

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2008-10-06

Fuljett ta 'informazzjoni

                                84
B. PACKAGE LEAFLET
85
PACKAGE LEAFLET: INFORMATION FOR THE USER
OLANZAPINE MYLAN 2.5 MG FILM-COATED TABLETS
OLANZAPINE MYLAN 5 MG FILM-COATED TABLETS
OLANZAPINE MYLAN 7.5 MG FILM-COATED TABLETS
OLANZAPINE MYLAN 10 MG FILM-COATED TABLETS
OLANZAPINE MYLAN 15 MG FILM-COATED TABLETS
OLANZAPINE MYLAN 20 MG FILM-COATED TABLETS
olanzapine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Olanzapine Mylan is and what it is used for
2.
What you need to know before you take Olanzapine Mylan
3.
How to take Olanzapine Mylan
4.
Possible side effects
5.
How to store Olanzapine Mylan
6.
Contents of the pack and other information
_ _
1.
WHAT OLANZAPINE MYLAN IS AND WHAT IT IS USED FOR
Olanzapine Mylan contains the active substance olanzapine. Olanzapine
belongs to a group of
medicines called antipsychotics and is used to treat the following
conditions:
•
Schizophrenia, a disease with symptoms such as hearing, seeing or
sensing things which are not
there, mistaken beliefs, unusual suspiciousness, and becoming
withdrawn. People with this
disease may also feel depressed, anxious or tense.
•
Moderate to severe manic episodes, a condition with symptoms of
excitement or euphoria.
Olanzapine Mylan has been shown to prevent recurrence of these
symptoms in patients with bipolar
disorder whose manic episode has responded to olanzapine treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE OLANZAPINE MYLAN
DO NOT TAKE OLANZAPINE MYLAN
•
if you are allergic (hypersensitive) to olanzapine, peanut or soya or
any 
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Olanzapine Mylan 2.5 mg film-coated tablets
Olanzapine Mylan 5 mg film-coated tablets
Olanzapine Mylan 7.5 mg film-coated tablets
Olanzapine Mylan 10 mg film-coated tablets
Olanzapine Mylan 15 mg film-coated tablets
Olanzapine Mylan 20 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Olanzapine Mylan 2.5 mg film-coated tablets
Each film-coated tablet contains 2.5 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 76 mg lactose (as monohydrate).
The film-coating of each 2.5 mg tablet contains 0.06 mg soya lecithin.
Olanzapine Mylan 5 mg film-coated tablets
Each film-coated tablet contains 5 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 152 mg lactose (as monohydrate).
The film-coating of each 5 mg tablet contains 0.12 mg soya lecithin.
Olanzapine Mylan 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 228 mg lactose (as monohydrate).
The film-coating of each 7.5 mg tablet contains 0.18 mg soya lecithin.
Olanzapine Mylan 10 mg film-coated tablets
Each film-coated tablet contains 10 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 304 mg lactose (as monohydrate).
The film-coating of each 10 mg tablet contains 0.24 mg soya lecithin.
Olanzapine Mylan 15 mg film-coated tablets
Each film-coated tablet contains 15 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 183 mg lactose (as monohydrate).
The film-coating of each 15 mg tablet contains 0.15 mg soya lecithin.
Olanzapine Mylan 20 mg film-coated tablets
Each film-coated tablet contains 20 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 244 mg lactose (as monohydrate).
The film-coating of each 20 mg tablet contains 0.20 mg soya lecithin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Olanzap
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 14-07-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 16-10-2008
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 14-07-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 16-10-2008
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 14-07-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 16-10-2008
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 14-07-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 16-10-2008
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 14-07-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 16-10-2008
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 14-07-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 16-10-2008
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 14-07-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 16-10-2008
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 14-07-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 16-10-2008
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 14-07-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 14-07-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 14-07-2023

Fittex twissijiet relatati ma 'dan il-prodott

Ara l-istorja tad-dokumenti